Key Takeaways
- • Novo Holdings appointed Amit Kakar as Head of Asia to establish a dedicated life sciences investment platform across China, Japan, Singapore, and Southeast Asia, marking the firm's geographic expansion beyond Europe and the United States.
- • The firm will deploy capital across three life sciences investment verticals in Asia: Principal Investments (sizable positions in established companies), Novo Growth (expansion capital for high-growth firms), and Novo Ventures (early-stage biotech and medtech).
- • Novo Holdings, managing USD 62 billion in assets, views Asia's life sciences sector as a "compelling area" driven by favorable demographics, accelerating R&D investment, and a rapidly maturing investment ecosystem.
- • Amit Kakar brings over 30 years of healthcare sector experience, including senior operational roles at GE Healthcare and an established track record as an investor and business leader.
- • Chaerhan Chun was appointed to the Novo Advisory Group to support Asia investment activities, including analysis and monitoring of life science portfolio companies in the region.
Summary
Novo Holdings, one of the world's largest life sciences investors with USD 62 billion in assets under management, has formalized its commitment to Asia by establishing a dedicated regional investment platform and appointing Amit Kakar as Managing Partner and Head of Asia. The appointment, announced in August 2020, signals Novo Holdings' strategic pivot to capture growth opportunities in an increasingly dynamic life sciences ecosystem across Asia's key markets: China, Japan, Singapore, and Southeast Asia.
The expansion reflects Novo Holdings' assessment that Asia represents a compelling investment opportunity distinct from its existing European and U.S. operations. According to Kasim Kutay, CEO of Novo Holdings, the region's favorable demographic trends, accelerating focus on innovation and R&D spending, and rapidly developing investment infrastructure position Asia as a natural extension of the firm's long-term, partnership-oriented investment thesis. While Novo Holdings has previously invested in Asia through its Financial Investments portfolio, the establishment of a dedicated life sciences team marks a material escalation in regional focus and capital deployment.
The Asia platform will operate across three core investment verticals. Principal Investments will target sizable positions in leading, established life sciences companies; Novo Growth will provide expansion capital to high-growth enterprises; and Novo Ventures will deploy capital into early-stage biotech and medical technology startups. This multi-stage approach enables Novo Holdings to maintain its characteristic long-term value creation mindset across the investment spectrum.
Kakar, who brings more than 30 years of healthcare industry experience including senior management roles at GE Healthcare, is tasked with leading both direct investments and strategic partnership development across the region. Supporting his efforts, Chaerhan Chun was appointed to the Novo Advisory Group to assist in analyzing and monitoring life science investments in Asia. The combination of experienced leadership and analytical support infrastructure underscores Novo Holdings' operational commitment to establishing a first-class Asia presence.
The expansion reflects Novo Holdings' assessment that Asia represents a compelling investment opportunity distinct from its existing European and U.S. operations. According to Kasim Kutay, CEO of Novo Holdings, the region's favorable demographic trends, accelerating focus on innovation and R&D spending, and rapidly developing investment infrastructure position Asia as a natural extension of the firm's long-term, partnership-oriented investment thesis. While Novo Holdings has previously invested in Asia through its Financial Investments portfolio, the establishment of a dedicated life sciences team marks a material escalation in regional focus and capital deployment.
The Asia platform will operate across three core investment verticals. Principal Investments will target sizable positions in leading, established life sciences companies; Novo Growth will provide expansion capital to high-growth enterprises; and Novo Ventures will deploy capital into early-stage biotech and medical technology startups. This multi-stage approach enables Novo Holdings to maintain its characteristic long-term value creation mindset across the investment spectrum.
Kakar, who brings more than 30 years of healthcare industry experience including senior management roles at GE Healthcare, is tasked with leading both direct investments and strategic partnership development across the region. Supporting his efforts, Chaerhan Chun was appointed to the Novo Advisory Group to assist in analyzing and monitoring life science investments in Asia. The combination of experienced leadership and analytical support infrastructure underscores Novo Holdings' operational commitment to establishing a first-class Asia presence.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.